Drug rechallenge and treatment beyond progression-implications for drug resistance

Elizabeth A. Kuczynski, Daniel J. Sargent, Axel Grothey, Robert S. Kerbel

Research output: Contribution to journalReview articlepeer-review

160 Scopus citations


The established dogma in oncology for managing recurrent or refractory disease dictates that therapy is changed at disease progression, because the cancer is assumed to have become drug-resistant. Drug resistance, whether pre-existing or acquired, is largely thought to be a stable and heritable process; thus, reuse of therapeutic agents that have failed is generally contraindicated. Over the past few decades, clinical evidence has suggested a role for unstable, non-heritable mechanisms of acquired drug resistance pertaining to chemotherapy and targeted agents. There are many examples of circumstances where patients respond to reintroduction of the same therapy (drug rechallenge) after a drug holiday following disease relapse or progression during therapy. Additional, albeit limited, evidence suggests that, in certain circumstances, continuing a therapy beyond disease progression can also have antitumour activity. In this Review, we describe the anticancer agents used in these treatment strategies and discuss the potential mechanisms explaining the apparent tumour re-sensitization with reintroduced or continued therapy. The extensive number of malignancies and drugs that challenge the custom of permanently switching to different drugs at each line of therapy warrants a more in-depth examination of the definitions of disease progression and drug resistance and the resulting implications for patient care.

Original languageEnglish (US)
Pages (from-to)571-587
Number of pages17
JournalNature Reviews Clinical Oncology
Issue number10
StatePublished - Oct 2013

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Drug rechallenge and treatment beyond progression-implications for drug resistance'. Together they form a unique fingerprint.

Cite this